// App-Quantinova.ai

TPS17 : Phase I/II trial of pembrolizumab in combination with binimetinib in unresectable locally advanced or metastatic triple negative breast cancer.

Researchers

Presenter

  • Saranya Chumsri

Principal Investigators

  • Mei-Yin Polley

  • Sarah L. Anderson

  • Ciara Catherine Maria O'Sullivan

  • Gerardo Colon-Otero

  • Keith L Knutson

  • E Aubrey Thompson

  • Alvaro Moreno-Aspitia

Medical Centers

  • Mayo Clinic, Jacksonville, FL

  • Mayo Clinic, Rochester, MN

  • CCR, NIH, Bethesda, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Phospho-ERK

  • Circulating tumor cells

  • Programmed death-ligand 1

  • tumor-infiltrating lymphocytes

Drug/Treatment

  • Pembrolizumab

  • Binimetinib

Outcome

  • N/A

Study Design

  • Single Arm

Phase

  • I/II

Study Id's

  • NCT03106415

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved